Standard of care radiotherapy

RADIATION2 trials

Sponsors

Dana-Farber Cancer Institute, University of Oxford

Conditions

HER2 Gene MutationLocally Advanced Non-Small Cell Lung CancerSalivary Gland Cancer

Phase 1

Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC

CompletedNCT04648033

University of OxfordLocally Advanced Non-Small Cell Lung Cancer

Start: 2020-12-07End: 2023-10-02Updated: 2026-01-29

Phase 2

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

RecruitingNCT04620187

Dana-Farber Cancer InstituteHER2 Gene Mutation, Salivary Gland Cancer

Start: 2020-12-24End: 2029-02-01Target: 55Updated: 2026-02-24

Related Papers

A phase 2 clinical trial of adjuvant ado-trastuzumab emtansine (T-DM1) for patients with HER2-positive salivary gland cancer.

Journal of Clinical Oncology2025-05-28